Total Payments
$2,944
2024 Payments
$206.89
Companies
23
Transactions
195
Medicare Patients
1,138
Medicare Billing
$77,395
Payment Breakdown by Category
Food & Beverage$2,893 (98.3%)
Education$50.67 (1.7%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,893 | 191 | 98.3% |
| Education | $50.67 | 4 | 1.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $426.38 | 33 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $417.26 | 25 | $0 (2023) |
| Novo Nordisk Inc | $308.23 | 23 | $0 (2021) |
| Abbott Laboratories | $293.86 | 15 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $209.32 | 11 | $0 (2018) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $209.05 | 12 | $0 (2024) |
| Amgen Inc. | $193.61 | 13 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $193.21 | 11 | $0 (2024) |
| ABBVIE INC. | $165.30 | 9 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $154.11 | 18 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $206.89 | 10 | Lilly USA, LLC ($68.80) |
| 2023 | $294.55 | 15 | Bayer Healthcare Pharmaceuticals Inc. ($76.43) |
| 2022 | $156.93 | 9 | Bayer HealthCare Pharmaceuticals Inc. ($62.28) |
| 2021 | $233.20 | 14 | AbbVie Inc. ($71.69) |
| 2020 | $53.50 | 3 | Insulet Corporation ($26.20) |
| 2019 | $104.87 | 6 | Abbott Laboratories ($56.31) |
| 2018 | $659.71 | 46 | SANOFI-AVENTIS U.S. LLC ($148.53) |
| 2017 | $1,234 | 92 | AstraZeneca Pharmaceuticals LP ($155.90) |
All Payment Transactions
195 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/27/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $19.90 | General |
| Category: Diabetes | ||||||
| 08/01/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $18.70 | General |
| 06/11/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $21.52 | General |
| Category: Diabetes | ||||||
| 05/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $23.65 | General |
| 04/18/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $22.15 | General |
| Category: Cardio-renal | ||||||
| 04/02/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $19.13 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 03/21/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $27.38 | General |
| Category: Diabetes | ||||||
| 02/22/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $16.22 | General |
| Category: Cardio-renal | ||||||
| 02/08/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $17.54 | General |
| 01/26/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $20.70 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/26/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $17.75 | General |
| 09/25/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $14.01 | General |
| Category: Cardio-renal | ||||||
| 09/21/2023 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $18.57 | General |
| Category: Diabetes | ||||||
| 08/31/2023 | ABBVIE INC. | SYNTHROID (Drug) | Food and Beverage | In-kind items and services | $22.26 | General |
| Category: IMMUNOLOGY | ||||||
| 08/24/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $19.26 | General |
| Category: Cardio-renal | ||||||
| 08/23/2023 | Horizon Therapeutics plc | TEPEZZA (Drug) | Food and Beverage | In-kind items and services | $20.02 | General |
| Category: TEPEZZA | ||||||
| 08/10/2023 | Lilly USA, LLC | BAQSIMI (Drug), JARDIANCE | Food and Beverage | In-kind items and services | $19.50 | General |
| Category: Diabetes | ||||||
| 06/15/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $22.88 | General |
| 05/11/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $19.63 | General |
| 05/09/2023 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.76 | General |
| Category: Diabetes | ||||||
| 04/27/2023 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $17.04 | General |
| Category: Diabetes Care | ||||||
| 03/30/2023 | ABBVIE INC. | SYNTHROID (Drug) | Food and Beverage | In-kind items and services | $21.10 | General |
| Category: IMMUNOLOGY | ||||||
| 03/09/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $20.37 | General |
| Category: Cardio-renal | ||||||
| 02/09/2023 | SANOFI-AVENTIS U.S. LLC | SOLIQUA 100/33 (Biological) | Food and Beverage | In-kind items and services | $18.61 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 01/26/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $22.79 | General |
| Category: Cardio-renal | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 263 | 401 | $82,532 | $18,619 |
| 2022 | 6 | 236 | 348 | $47,534 | $17,517 |
| 2021 | 6 | 303 | 443 | $55,835 | $22,218 |
| 2020 | 8 | 336 | 440 | $61,758 | $19,041 |
Total Patients
1,138
Total Services
1,632
Medicare Billing
$77,395
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 90 | 152 | $55,176 | $12,177 | 22.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 32 | 39 | $9,984 | $1,945 | 19.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 24 | $4,800 | $1,327 | 27.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 13 | 13 | $6,110 | $1,051 | 17.2% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 62 | 101 | $2,424 | $961.52 | 39.7% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 24 | 38 | $3,800 | $924.48 | 24.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 31 | 34 | $238.00 | $233.24 | 98.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 95 | 162 | $37,584 | $13,123 | 34.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 28 | 33 | $5,214 | $2,076 | 39.8% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 69 | 106 | $2,544 | $1,010 | 39.7% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 14 | 15 | $1,380 | $806.01 | 58.4% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2022 | 12 | 12 | $672.00 | $442.33 | 65.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 18 | 20 | $140.00 | $59.13 | 42.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 98 | 169 | $39,208 | $14,676 | 37.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 49 | 58 | $9,164 | $3,586 | 39.1% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2021 | 39 | 42 | $2,352 | $1,352 | 57.5% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 19 | 22 | $2,024 | $1,350 | 66.7% |
| 83036 | Hemoglobin a1c level | Office | 2021 | 72 | 119 | $2,856 | $1,155 | 40.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 26 | 33 | $231.00 | $99.00 | 42.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 131 | 188 | $43,616 | $12,868 | 29.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 39 | 47 | $7,426 | $1,987 | 26.8% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 14 | 14 | $4,886 | $1,573 | 32.2% |
| 83036 | Hemoglobin a1c level | Office | 2020 | 91 | 128 | $3,072 | $1,233 | 40.1% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2020 | 23 | 24 | $1,315 | $691.58 | 52.6% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 11 | 11 | $910.00 | $540.36 | 59.4% |
About Dr. David Odegaard, MD
Dr. David Odegaard, MD is a Internal Medicine healthcare provider based in Omaha, Nebraska. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/23/2007. The National Provider Identifier (NPI) number assigned to this provider is 1023236213.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Odegaard, MD has received a total of $2,944 in payments from pharmaceutical and medical device companies, with $206.89 received in 2024. These payments were reported across 195 transactions from 23 companies. The most common payment nature is "Food and Beverage" ($2,893).
As a Medicare-enrolled provider, Odegaard has provided services to 1,138 Medicare beneficiaries, totaling 1,632 services with total Medicare billing of $77,395. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Diabetes & Metabolism
- Location Omaha, NE
- Active Since 04/23/2007
- Last Updated 03/07/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1023236213
Products in Payments
- FARXIGA (Drug) $209.32
- JARDIANCE (Drug) $197.03
- Kerendia (Drug) $193.21
- TOUJEO (Drug) $169.27
- HUMULIN (Drug) $156.86
- INVOKANA (Drug) $148.09
- Prolia (Biological) $145.32
- SYNTHROID (Drug) $134.55
- FreeStyle Libre blood glucose Flash Monitoring System (Device) $125.02
- TOUJEO (Biological) $115.73
- Victoza (Drug) $114.07
- Ozempic (Drug) $106.43
- Omnipod (Device) $103.10
- SOLIQUA (Drug) $86.56
- FreeStyle Libre Pro (Device) $76.38
- FreeStyle Libre (Device) $56.31
- t-slim insulin pump (Device) $55.32
- NATPARA (Drug) $53.04
- FORTEO (Drug) $49.00
- BAQSIMI (Drug) $36.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Omaha
Mojtaba Akhtari, M.d, M.D
Internal Medicine — Payments: $1.6M
Internal Medicine $1.6M
Dr. Matthew Lunning, D.o, D.O
Internal Medicine — Payments: $650,808
Internal Medicine $650,808
Michael Dunn, M.d, M.D
Internal Medicine — Payments: $221,491
Internal Medicine $221,491
Dr. Brian Boer, M.d., Ph.d, M.D., PH.D
Internal Medicine — Payments: $96,162
Internal Medicine $96,162
Dr. Trevor Van Schooneveld, M.d, M.D
Internal Medicine — Payments: $91,007
Internal Medicine $91,007
Dr. Michael Schafer, Md, MD
Internal Medicine — Payments: $60,335
Internal Medicine $60,335